Nitrase Therapeutics
PrivateLast Round
Grant
Apr 5, 2022
Total Funding Raised
$84.75M
Company Overview
Nitrase Therapeutics is a biopharmaceutical company that develops therapies targeting a wide range of diseases by utilizing its innovative platform focused on the biochemical modification of proteins through nitration.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nitrase Therapeutics Comparables
Compare Nitrase Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Belharra | 70% | |
| Vanqua Bio | 69% | |
| Amphista Therapeutics | 66% |
Nitrase Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 5, 2022 | ||||
| Series A | Nov 2, 2021 | ||||
| Series A | Apr 21, 2020 | ||||
| Grant | Jun 12, 2019 | ||||
| Seed | Jul 12, 2018 |
Nitrase Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AbbVie Ventures | Series A |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Alexandria Venture Investments | Series A |
| Sofinnova Partners | Series A |
| Mission Bay Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2026
Monthly visitors increased 56% MoM.
- Mar 20, 2025
Discovered glyoxalase domain-containing protein 4 (GLOD4), which catalyzes selective protein nitration.
Nitrase Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nitrase Therapeutics's valuation, stock price, and market status.
Is Nitrase Therapeutics a public or private company?
Nitrase Therapeutics is a private company.
What is the current stock price of Nitrase Therapeutics?
Nitrase Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Nitrase Therapeutics worth (valuation)?
Valuation information for Nitrase Therapeutics is not publicly available.
Can I buy Nitrase Therapeutics stock?
Nitrase Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Nitrase Therapeutics's last funding round?
Nitrase Therapeutics's most recent funding round was Grant on April 5, 2022.
Who are the main investors in Nitrase Therapeutics?
Key investors in Nitrase Therapeutics include AbbVie Ventures, The Michael J. Fox Foundation for Parkinson's Research, Sofinnova Partners.
Will Nitrase Therapeutics IPO soon?
No public IPO plans have been announced for Nitrase Therapeutics.
How can I track Nitrase Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Nitrase Therapeutics's secondary market activity and sign up for updates.